Boston Therapeutics (BTHE) 0.0497 $BTHE
Boston Therapeutics' sugardown(R) in Clinical Trials Reduces Glucose, Fructose and Insulin
Marketwired - Tue Dec 29, 7:54AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) released final trial results from its proof of concept (POC) Sydney University study that showed consumption of sugardown(R) tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a favorable response. Specifically, two sugardown(R) tablets were found to reduce glucose levels (and by association fructose exposure) by up to 20 percent and the insulin response by up to 14 percent. Four sugardown(R) tablets were found to reduce total glucose levels by up to 28 percent and insulin response by up to18 percent. The study results indicate an average reduction in glycemic index (GI) an important measure of healthy nutritional management of approximately 10 percent following soft drink consumption with two sugardown(R) tablets.
Boston Therapeutics, Inc. Reports Third Quarter Results and Provides Corporate Update
Marketwired - Fri Nov 20, 3:58PM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of novel compounds based on complex carbohydrate chemistry for the treatment of metabolic disease and inflammatory disease states, today reported its financial results for the third quarter and nine months ended September 30, 2015 and provided a corporate update.
Boston Therapeutics Completes Enrollment for BTI-320 Clinical Trial
Marketwired - Tue Oct 06, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), completed enrollment for the clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial had 60 pre-diabetic patients.
Boston Therapeutics Pays Off Convertible Promissory Notes
Marketwired - Tue Sep 29, 12:51PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) (the "Company"
announced that on September 24, 2015, the Company paid in-full all of the Company's outstanding variable rate Convertible Promissory Notes (collectively, the "Notes" in the aggregate amount of $524,000.00 and cancelled all related Common Stock Purchase Warrants (collectively, the "Warrants". The Company paid off the Notes and cancelled the Warrants using a portion of the proceeds of a recent financing provided to the Company by one of its directors. As part of the recent financing, the Company issued additional convertible notes that convert into common stock at a fixed conversion price. As a result of the full payment of the Notes, the Notes are no longer a debt obligation of the Company and, as such, are no longer convertible into shares of the Company's common stock.
Boston Therapeutics' BTI-320 in Clinical Trial Significantly Reduces Both Glucose and Fructose Levels in Blood
Marketwired - Tue Sep 15, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), is conducting a clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial has enrolled 56 of the planned 60 pre-diabetic patients. Also, the interim clinical analysis in the proof of concept trial demonstrate up to 77% reduction in Glucose and up to 27% in Fructose.
Boston Therapeutics, Inc. Reports Second Quarter Results and Provides Corporate Update
Marketwired - Thu Aug 13, 2:20PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of novel compounds based on complex carbohydrate chemistry for the treatment of diabetes and inflammatory disease, today reported its financial results for the second quarter and six months ended June 30, 2015 and provided a corporate update.
Boston Therapeutics Nominates Philip Getter to Board of Directors
Marketwired - Thu Aug 06, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has nominated Philip Getter to its Board of Directors, effective immediately. This increases the total number of Board members to nine.
Boston Therapeutics' Hong Kong Affiliate Advance Pharmaceutical's BTI-320 Clinical Trial Reaches Mid-Point by Enrolling 30 Patients at the Chinese University of Hong Kong
Marketwired - Wed Jul 08, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), is conducting a clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial has enrolled 30 of the planned 60 patients. Also, the interim analysis in the proof of concept trial is due to be reported shortly.
Boston Therapeutics Presents Findings of BTI-320, a Novel, Non-Systemic, Non-Hypoglycemic Drug Candidate as Therapy to Manage Blood Glucose at 75th Annual Meeting of the American Diabetes Association
Marketwired - Mon Jun 08, 5:19AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will present data on BTI-320, its novel, non-systemic, non-hypoglycemic drug candidate to manage blood glucose, as a poster presentation at the 75th Annual Meeting of the American Diabetes Association being held in Boston, June 5th to the 9th.
Boston Therapeutics, Inc. Reports First Quarter Results and Provides Corporate Update
Marketwired - Wed May 20, 3:55PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the first quarter and three months ended March 31, 2015 and provided a corporate update.
Boston Therapeutics' Affiliate Advanced Pharmaceutical Initiates SUGARDOWN(R) Clinical Trial in Hong Kong
Marketwired - Wed Mar 25, 5:37AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), affiliate in Hong Kong, Advance Pharmaceutical Company, Ltd. (APC), initiated enrollment of the first subjects in a clinical trial at The Chinese University of Hong Kong to evaluate the effects of SUGARDOWN(R) who are pre-diabetic. (Trial posted on ClinicalTrials.gov)
Boston Therapeutics and Advance Pharmaceutical Expand sugardown(R) Licensing Agreement to Japan; Increases Number of Asian Countries to 16
Marketwired - Tue Mar 17, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of complex carbohydrates to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd. (APC), via its subsidiary Sugardown Company Ltd.(SDCL) of Hong Kong, have agreed to expand their licensing and marketing agreement for Boston Therapeutics' sugardown(R) to include Japan. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as APC continues its market registration expansion.
WSA Medical Spotlight
Marketwired - Tue Feb 17, 1:00PM CST
Hansen Medical, Inc.'s (NASDAQ: HNSN) CEO Cary Vance discussed the company's robotic systems and catheters as well as their recent IVC filter retrieval breakthrough. Mr. Vance stated he believes Hansen's technology addresses many key trends and issues hospitals are facing today including revenue-generation and cost containment. He talked about some of the benefits the IVC filter provides patients such as much safer and more effective procedures. Mr. Vance outlined upcoming milestones, stating that Hansen expects to have a new 10 French Magellan Robotic Catheter to allow for new procedures in their vascular space. He also shared HNSN's global expansion strategy and goals for their electrophysiology business.
HNSN: 3.98 (-0.01), ISR: 0.92 (+0.12)
Boston Therapeutics' Hong Kong Affiliate Receives Department of Health Certificate to Initiate SUGARDOWN(R) Clinical Trial
Marketwired - Tue Jan 27, 6:34AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), received a signed certificate from the Department of Health to initiate a clinical trial at The Chinese University of Hong Kong (CUHK) evaluating SUGARDOWN(R) in subjects with pre-diabetes. The clinical trial is expected to start this quarter.
Boston Therapeutics' sugardown(R) Significantly Reduces Glucose, Fructose and Insulin Levels in Sugary Soft Drinks
Marketwired - Tue Jan 20, 6:01AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) released additional trial results from its Sydney University study that showed consumption of sugardown(R) tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a reduction response. Specifically, two sugardown(R) tablets were found to reduce glucose and fructose levels by up to a total of 20 percent and insulin levels by up to 14 percent. Four sugardown(R) tablets were found to reduce total glucose and fructose levels by up to 28 percent and insulin levels by up to18 percent. These new data, which includes fructose levels, are in addition to the topline study results that were announced earlier this month that there was an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with two sugardown(R) tablets.
Boston Therapeutics to Present at 8th Annual OneMedForum Conference in San Francisco
Marketwired - Wed Jan 07, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will be a presenting company at the 8th Annual OneMedForum Conference to be held at the San Francisco Marriott Marquis in San Francisco, CA.
Boston Therapeutics' sugardown(R) Shown to Reduce Glucose Levels Following Consumption of Sugary Beverages
Marketwired - Tue Jan 06, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, announced that a study at Sydney University's Glycemic Index Research Service (SUGiRS) demonstrated an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with sugardown(R). The now-completed trial, which was co-sponsored by Boston Therapeutics and SugarDown Co Ltd (Hong Kong), was the first to evaluate sugardown(R)'s effectiveness with sugary beverages. The primary outcomes of the study were postprandial incremental glucose area under the curve (iAUC) and postprandial incremental insulin area under the curve (iAUC).
Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss
Marketwired - Wed Dec 10, 7:21AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that the U.S. Food and Drug Administration ("FDA" has accepted the company's Investigational New Drug Application ("IND" for BTI-320 to treat Type 2 diabetes and weight management. The primary endpoints for the multicenter trial are the mean change in Hemoglobin A1c (or HbA1c) and weight loss. The Joslin Diabetes Center in Boston will be the lead clinic in the trial, which is planned to begin in the first quarter of 2015.
Boston Therapeutics and Advance Pharmaceutical Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia
Marketwired - Fri Nov 21, 6:41AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd., via its subsidiary Sugardown Company Ltd. of Hong Kong, have agreed to expand their marketing agreement for Boston Therapeutics' sugardown(R) to include 12 additional countries in Asia. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as Advance continues its market registration expansion.
Boston Therapeutics' sugardown(R) in Clinical Trials Reduces Glucose, Fructose and Insulin
Marketwired - Tue Dec 29, 7:54AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) released final trial results from its proof of concept (POC) Sydney University study that showed consumption of sugardown(R) tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a favorable response. Specifically, two sugardown(R) tablets were found to reduce glucose levels (and by association fructose exposure) by up to 20 percent and the insulin response by up to 14 percent. Four sugardown(R) tablets were found to reduce total glucose levels by up to 28 percent and insulin response by up to18 percent. The study results indicate an average reduction in glycemic index (GI) an important measure of healthy nutritional management of approximately 10 percent following soft drink consumption with two sugardown(R) tablets.
Boston Therapeutics, Inc. Reports Third Quarter Results and Provides Corporate Update
Marketwired - Fri Nov 20, 3:58PM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of novel compounds based on complex carbohydrate chemistry for the treatment of metabolic disease and inflammatory disease states, today reported its financial results for the third quarter and nine months ended September 30, 2015 and provided a corporate update.
Boston Therapeutics Completes Enrollment for BTI-320 Clinical Trial
Marketwired - Tue Oct 06, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), completed enrollment for the clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial had 60 pre-diabetic patients.
Boston Therapeutics Pays Off Convertible Promissory Notes
Marketwired - Tue Sep 29, 12:51PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) (the "Company"
announced that on September 24, 2015, the Company paid in-full all of the Company's outstanding variable rate Convertible Promissory Notes (collectively, the "Notes" in the aggregate amount of $524,000.00 and cancelled all related Common Stock Purchase Warrants (collectively, the "Warrants". The Company paid off the Notes and cancelled the Warrants using a portion of the proceeds of a recent financing provided to the Company by one of its directors. As part of the recent financing, the Company issued additional convertible notes that convert into common stock at a fixed conversion price. As a result of the full payment of the Notes, the Notes are no longer a debt obligation of the Company and, as such, are no longer convertible into shares of the Company's common stock. Boston Therapeutics' BTI-320 in Clinical Trial Significantly Reduces Both Glucose and Fructose Levels in Blood
Marketwired - Tue Sep 15, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), is conducting a clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial has enrolled 56 of the planned 60 pre-diabetic patients. Also, the interim clinical analysis in the proof of concept trial demonstrate up to 77% reduction in Glucose and up to 27% in Fructose.
Boston Therapeutics, Inc. Reports Second Quarter Results and Provides Corporate Update
Marketwired - Thu Aug 13, 2:20PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of novel compounds based on complex carbohydrate chemistry for the treatment of diabetes and inflammatory disease, today reported its financial results for the second quarter and six months ended June 30, 2015 and provided a corporate update.
Boston Therapeutics Nominates Philip Getter to Board of Directors
Marketwired - Thu Aug 06, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has nominated Philip Getter to its Board of Directors, effective immediately. This increases the total number of Board members to nine. Boston Therapeutics' Hong Kong Affiliate Advance Pharmaceutical's BTI-320 Clinical Trial Reaches Mid-Point by Enrolling 30 Patients at the Chinese University of Hong Kong
Marketwired - Wed Jul 08, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), is conducting a clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial has enrolled 30 of the planned 60 patients. Also, the interim analysis in the proof of concept trial is due to be reported shortly.
Boston Therapeutics Presents Findings of BTI-320, a Novel, Non-Systemic, Non-Hypoglycemic Drug Candidate as Therapy to Manage Blood Glucose at 75th Annual Meeting of the American Diabetes Association
Marketwired - Mon Jun 08, 5:19AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will present data on BTI-320, its novel, non-systemic, non-hypoglycemic drug candidate to manage blood glucose, as a poster presentation at the 75th Annual Meeting of the American Diabetes Association being held in Boston, June 5th to the 9th. Boston Therapeutics, Inc. Reports First Quarter Results and Provides Corporate Update
Marketwired - Wed May 20, 3:55PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the first quarter and three months ended March 31, 2015 and provided a corporate update.
Boston Therapeutics' Affiliate Advanced Pharmaceutical Initiates SUGARDOWN(R) Clinical Trial in Hong Kong
Marketwired - Wed Mar 25, 5:37AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), affiliate in Hong Kong, Advance Pharmaceutical Company, Ltd. (APC), initiated enrollment of the first subjects in a clinical trial at The Chinese University of Hong Kong to evaluate the effects of SUGARDOWN(R) who are pre-diabetic. (Trial posted on ClinicalTrials.gov)
Boston Therapeutics and Advance Pharmaceutical Expand sugardown(R) Licensing Agreement to Japan; Increases Number of Asian Countries to 16
Marketwired - Tue Mar 17, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of complex carbohydrates to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd. (APC), via its subsidiary Sugardown Company Ltd.(SDCL) of Hong Kong, have agreed to expand their licensing and marketing agreement for Boston Therapeutics' sugardown(R) to include Japan. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as APC continues its market registration expansion.
WSA Medical Spotlight
Marketwired - Tue Feb 17, 1:00PM CST
Hansen Medical, Inc.'s (NASDAQ: HNSN) CEO Cary Vance discussed the company's robotic systems and catheters as well as their recent IVC filter retrieval breakthrough. Mr. Vance stated he believes Hansen's technology addresses many key trends and issues hospitals are facing today including revenue-generation and cost containment. He talked about some of the benefits the IVC filter provides patients such as much safer and more effective procedures. Mr. Vance outlined upcoming milestones, stating that Hansen expects to have a new 10 French Magellan Robotic Catheter to allow for new procedures in their vascular space. He also shared HNSN's global expansion strategy and goals for their electrophysiology business.
HNSN: 3.98 (-0.01), ISR: 0.92 (+0.12)
Boston Therapeutics' Hong Kong Affiliate Receives Department of Health Certificate to Initiate SUGARDOWN(R) Clinical Trial
Marketwired - Tue Jan 27, 6:34AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), received a signed certificate from the Department of Health to initiate a clinical trial at The Chinese University of Hong Kong (CUHK) evaluating SUGARDOWN(R) in subjects with pre-diabetes. The clinical trial is expected to start this quarter.
Boston Therapeutics' sugardown(R) Significantly Reduces Glucose, Fructose and Insulin Levels in Sugary Soft Drinks
Marketwired - Tue Jan 20, 6:01AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) released additional trial results from its Sydney University study that showed consumption of sugardown(R) tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a reduction response. Specifically, two sugardown(R) tablets were found to reduce glucose and fructose levels by up to a total of 20 percent and insulin levels by up to 14 percent. Four sugardown(R) tablets were found to reduce total glucose and fructose levels by up to 28 percent and insulin levels by up to18 percent. These new data, which includes fructose levels, are in addition to the topline study results that were announced earlier this month that there was an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with two sugardown(R) tablets.
Boston Therapeutics to Present at 8th Annual OneMedForum Conference in San Francisco
Marketwired - Wed Jan 07, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will be a presenting company at the 8th Annual OneMedForum Conference to be held at the San Francisco Marriott Marquis in San Francisco, CA.
Boston Therapeutics' sugardown(R) Shown to Reduce Glucose Levels Following Consumption of Sugary Beverages
Marketwired - Tue Jan 06, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, announced that a study at Sydney University's Glycemic Index Research Service (SUGiRS) demonstrated an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with sugardown(R). The now-completed trial, which was co-sponsored by Boston Therapeutics and SugarDown Co Ltd (Hong Kong), was the first to evaluate sugardown(R)'s effectiveness with sugary beverages. The primary outcomes of the study were postprandial incremental glucose area under the curve (iAUC) and postprandial incremental insulin area under the curve (iAUC).
Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss
Marketwired - Wed Dec 10, 7:21AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that the U.S. Food and Drug Administration ("FDA"
has accepted the company's Investigational New Drug Application ("IND" for BTI-320 to treat Type 2 diabetes and weight management. The primary endpoints for the multicenter trial are the mean change in Hemoglobin A1c (or HbA1c) and weight loss. The Joslin Diabetes Center in Boston will be the lead clinic in the trial, which is planned to begin in the first quarter of 2015. Boston Therapeutics and Advance Pharmaceutical Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia
Marketwired - Fri Nov 21, 6:41AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd., via its subsidiary Sugardown Company Ltd. of Hong Kong, have agreed to expand their marketing agreement for Boston Therapeutics' sugardown(R) to include 12 additional countries in Asia. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as Advance continues its market registration expansion.
